Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2347MR)

This product GTTS-WQ2347MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ2347MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5993MR IVTScrip™ mRNA-Anti-ITGAV&ITGB3, CNTO 095(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 095
GTTS-WQ10591MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY-3127804
GTTS-WQ73MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ2440MR IVTScrip™ mRNA-Anti-TSLP, AMG 157(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA AMG 157
GTTS-WQ7363MR IVTScrip™ mRNA-Anti-FZD7, FZD8-Fc(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA FZD8-Fc
GTTS-WQ6918MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ENB-0040
GTTS-WQ8632MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ6503MR IVTScrip™ mRNA-Anti-CD274, CX-072(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA CX-072
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW